-
Posted by
Two Blokes Jun 16 -
Filed in
Stock
-
8 views
INmune Bio offers a high-risk, high-reward opportunity ahead of its Phase 2 Alzheimer's readout. Lead asset XPro1595's mechanism of selectively targeting soluble TNF (sTNF) has strong preclinical, mechanistic, and limited but encouraging Phase 1b data. If XPro1595 delivers positive results, it could validate a new approach in Alzheimer's and other inflammatory diseases, but the investment remains speculative due to clinical and market risks.
